BRCTF (BioArctic AB) Moat Score: 6/10 (As of Jul. 04, 2026)


BRCTF BioArctic AB BRCTF
84 GF Score
Price $35.00
GF Value $49.02
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is BioArctic AB Moat Score?

BioArctic AB BRCTF 84 Moat Score is 6 as of Jul. 04, 2026. GuruFocus rates BRCTF with a GF Score™ of 84/100 and a GF Value™ of $49.02 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,399 Biotechnology companies, BioArctic AB ranks better than 98.93% on this metric.

BioArctic AB has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

BioArctic AB has Narrow Moat: BioArctic AB has a strong narrow moat due to its valuable intellectual property and patents in the biotech sector. The company benefits from significant R&D capabilities and regulatory barriers, but its market share and distribution network are still developing.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BioArctic AB might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

BioArctic AB  (OTCPK:BRCTF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BioArctic AB Moat Score Related Terms

BRCTF vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, BioArctic AB's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioArctic AB Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's Moat Score distribution charts can be found below:

* The bar in red indicates where BioArctic AB's Moat Score falls into.


BRCTF
84GF Score
BioArctic AB BRCTF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
BioArctic AB (BRCTF) has a Moat Score of 6 as of Jul. 04, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BioArctic AB ranks #15 out of 1399 companies in the Biotechnology industry, placing it in the top 1.1%.
Is BioArctic AB's Moat Score too high?
BioArctic AB's current Moat Score is 6. The Biotechnology industry median Moat Score is 2.00. BioArctic AB's value of 6 is 200% above this industry median. Based on the distribution chart, BioArctic AB ranks #15 out of 1399 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioArctic AB has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioArctic AB's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioArctic AB ranks #15 out of 1399 companies for Moat Score. This places BioArctic AB in the top 1% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. BioArctic AB's value of 6 is 200% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioArctic AB's current Moat Score of 6 is 200% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioArctic AB's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioArctic AB stock overvalued right now?
Based on GuruFocus' analysis, BioArctic AB (BRCTF) is currently considered Modestly Undervalued. The stock's GF Value™ is $49.02, compared to a current price of $35.00 — trading 28.6% below its estimated fair value. The current Moat Score is 6 and 200% above the Biotechnology industry median of 2.00. BioArctic AB's overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BioArctic AB (BRCTF), the current Moat Score is 6 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioArctic AB (BRCTF) Overvalued in 2026?

Based on GuruFocus' analysis, BioArctic AB stock appears to be undervalued. The current stock price of $35.00 is trading 28.6% below its estimated GF Value™ of $49.02. GuruFocus considers BioArctic AB to be Modestly Undervalued.

Key valuation signals for BRCTF:

  • Moat Score: 6
  • GF Value™: $49.02 vs. price of $35.00 (28.6% below fair value)
  • GF Score™: 84/100 with 2 warning signs
  • Industry Position: 200% above the Biotechnology median (#15 of 1399)

No single metric tells the full story. See the BRCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioArctic AB Business Description

Address Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.
84GF Score

Get the complete analysis for BRCTF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.00
Price
$49.02
GF Value